Research ArticleClinical Studies

Platinum-based Doublet Chemotherapy plus Bevacizumab Without Bevacizumab Maintenance in Advanced Non-small Cell Lung Cancer (NSCLC)

DORTE SCHOU NØRØXE, SANDRA WALLEREK and JENS BENN SØRENSEN
Anticancer Research August 2013, 33 (8) 3275-3278;

Article Figures & Data

Figures

  • Figure 1.
    Figure 1.

    KaplanMeier estimates of overall survival (A) and progression-free survival (B) in 30 patients with advanced non-small cell lung cancer who received induction treatment of carboplatin/vinorelbine/bevacizumab without subsequent bevacizumab maintenance. Median OS in PS 0-1 patients is 8.8 months, 1-year survival 42%, and median PFS 4.5 months.

Tables

  • Table I.
  • Table II.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Platinum-based Doublet Chemotherapy plus Bevacizumab Without Bevacizumab Maintenance in Advanced Non-small Cell Lung Cancer (NSCLC)
DORTE SCHOU NØRØXE, SANDRA WALLEREK, JENS BENN SØRENSEN
Anticancer Research Aug 2013, 33 (8) 3275-3278;
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords